Press Releases

July 16, 2010

Takeda Pharmaceutical Company Limited

Approval of Lampion^® Pack in Japan for Secondary Eradication of Helicobacter pylori

Osaka, Japan, July 16, 2010 -Takeda Pharmaceutical Company Limited ("Takeda") today announced that Lampion^® Pack for secondary eradication of Helicobacter pylori^[*] (“H. Pylori”) was approved by the Ministry of Health, Labour and Welfare. Lampion Pack is a single pack containing lansoprazole (Japanese brand name: Takepron^® Capsules 30), amoxicillin hydrate (Japanese brand name: Amolin^® Capsules 250) and metronidazole.

A triple therapy with a proton pump inhibitor, amoxicillin hydrate and clarithromycin is the first eradication of H. Pylori for gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura and the stomach after endoscopic resection of early stage gastric cancer in Japan. In cases where H. Pylori is still not eradicated with this treatment, a secondary triple therapy regimen, replacing clarithromycin with metronidazole is also approved in Japan. Lampion Pack contains all three drugs required to be taken each day and provides better administration compliance for secondary eradication, which is expected to increase efficacy for secondary eradication of H. Pylori.

The infection ratio of H. Pylori in Japan is higher than Western countries. In addition to currently available Lansap^® for the first eradication of H. Pylori, Lampion Pack for the second eradication of H. Pylori is expected to provide a meaningful contribution to eradication of H. Pylori for patients and healthcare professionals.

^[*] H. Pylori is one of the bacteria commonly existing in the human stomach and is known to have the pivotal role mainly in the onset of peptic ulcers. The eradication of H. Pylori is therefore an effective treatment mainly for the prevention of recurrence of peptic ulcers, remarkably lowering the recurrence rate for patients with a history of peptic ulcers.

(Reference)

Indications	<Bacteria> Helicobacter pylori susceptible to amoxicillin hydrate and/or metronidazole <Infections> Helicobacter pylori infection in patients with followings Gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura or the stomach after endoscopic resection of early stage gastric cancer
Dosage and Administration	When Helicobacter pylori eradication with a proton pump inhibitor, amoxicillin hydrate, and clarithromycin fails, the usual adult dosage for oral administration is 30 mg of lansoprazole, 750 mg (potency) of amoxicillin hydrate, and 250mg of metronidazole twice daily taken together for seven days.

###